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Abstract C-CAM (rat cell CAM/human CD66a) is ubiquitous
and multifunctional. It is involved in intercellular adhesion, signal
transduction and cell growth inhibition. Structurally, it is related
to the carcinoembryonic antigen. In the present study serum, bile
and urine of rats with liver diseases were analyzed for the
presence of cell CAM. After bile duct ligation and during
galactosamine (GalN) hepatitis we found that large amounts of
liver membrane-bound C-CAM are secreted or shed into blood.
The serum level of another liver membrane-bound protein,
LI-cadherin, is not increased. It was shown that C-CAM is also
present in bile fluid, and for the first time that C-CAM is present
in the urine of rats with liver diseases. A particularly high
concentration was measured in the urine of rats suffering from
GalN hepatitis.
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1. Introduction
Rat C-CAM (cell-cell adhesion molecule), also known as
cell CAM, is a ubiquitous, highly glycosylated, transmem-
brane protein with an apparent Mr of 110 000 [1^6]. C-
CAM has been shown to be involved in di¡erent physiological
functions (for review see [7]). Isolated rat hepatocytes or C-
CAM transfected eukaryotic cells show strong cell-cell adhe-
sion. This adhesion can be inhibited by speci¢c antibodies
indicating an intercellular adhesion function for C-CAM.
For other carcinoembryonic antigen-related molecules, the
same adhesive activity could be demonstrated [8,9]. C-CAM
also acts as a bacterial and viral receptor [10^13], activates
neutrophilic granulocytes [14], might be involved in bile salt
export [15,16], serves as a substrate for di¡erent kinases [17^
19] and suppresses the growth of prostate, colonic or breast
cancer [20^22]. The involvement of C-CAM in di¡erent cellu-
lar functions suggests that loss of membrane-bound C-CAM
by shedding or limited proteolysis may represent a critical
response of the whole organism. In general only a few pro-
teins are secreted or shed into body £uids. Albumin, immu-
noglobulins, transport proteins and coagulation factors repre-
sent the major protein fraction in blood. In individuals
su¡ering from tumor growth, additional proteins are detect-
able in serum. Therefore some of these proteins, e.g. the car-
cinoembryonic antigen (CEA) [23,24], have been used as tu-
mor marker molecules. In the present study we used speci¢c
antibodies to detect rat C-CAM in serum, bile and urine.
From previous studies it is known that human C-CAM is
present in serum or bile [25,26], but a more detailed study
was needed to analyze whether it is useful for monitoring
distinct liver diseases. As a model system we selected rats
with liver diseases. Bile duct ligation was performed and D-
galactosamine (GalN)-hepatitis was induced by 2-amino-
2-deoxy-D-galactose [27]. As a tumor model we induced the
Morris hepatoma 7777 [28]. We showed that C-CAM is shed
into serum and bile, and that its serum level increases during
liver disease progression. For the ¢rst time we report the
presence of C-CAM in urine.
2. Materials and methods
2.1. Materials
Unless otherwise stated, chemicals and reagents were obtained from
Merck, Serva, Sigma or Life Technologies, Germany. The di¡erent
antisera and monoclonal antibodies have been characterized previ-
ously [6,29,30]. CHO wild type cells and Morris hepatoma (MH)
7777 cells were obtained from the American Tissue Culture Collection
(ATCC); CHO/C-CAM transfectants have been described previously
[31]. Wistar and Bu¡alo rats were inbred German stocks originally
derived from Charles River Wiga.
2.2. SDS-PAGE, immunoblot and immunoprecipitation analysis
SDS-PAGE and electroblotting were done according to standard
procedures. Membrane ¢lters were blocked in 5% non-fat dry milk
powder dissolved in PBS (150 mM NaCl, 0.3 mM KCl, 0.8 mM
Na2HPO4, 0.1 mM KH2PO4, pH 7.2)/0.1% Tween-20. Membranes
were incubated with the primary antibody and a peroxidase-coupled
goat anti-mouse IgG (Dianova, Hamburg, Germany), each for 1.5 h
at room temperature; antibody dilution was 0.5 Wg/ml in PBS/0.1%
Tween-20. Unbound antibodies were removed by three 15-min washes
in PBS/0.1% Tween-20, and detection was carried out using an en-
hanced chemiluminescence detection kit (Amersham Buchler,
Braunschweig, Germany) and X-ray exposure. For immunoprecipita-
tion, 20 Wl anti-C-CAM antiserum or anti-LI-cadherin antiserum was
coupled to protein A-Sepharose (Pharmacia, Uppsala, Sweden). Pre-
clearance of the antigen preparations with protein A-Sepharose
avoided unspeci¢c binding of proteins to the immunocomplex.
C-CAM was precipitated from body £uids or membranes at 4‡C over-
night in PBS/1% Triton X-100/1 mM PMSF. Immunocomplexes were
washed three times with 500 mM NaCl, 10 mM Tris-HCl pH 7.8,
1 mM EDTA, 1% Triton X-100, 1% BSA, 1 mM PMSF and twice
with PBS. For semi-quantitative purposes Western blot analysis of the
supernatants from all precipitation experiments was done. Staining of
C-CAM and LI-cadherin was no longer possible in the supernatants
after precipitation. Immunopuri¢ed antigens were applied to SDS-
PAGE under reducing conditions. C-CAM and LI-cadherin were de-
tected with the monoclonal antibodies Be 9.2 and 47.2, respectively, to
avoid unspeci¢c reactions during chemiluminescence detection. The
antigen detection limit was 10 fmol. The coe⁄cients of variation in
amounts of detected antigens were 5^15% in di¡erent experiments.
2.3. Preparation of serum, urine and liver membrane protein fractions
Blood was taken from rats, and serum prepared according to stand-
ard procedures. 0.5 mg membrane proteins, 0.3 ml 1:3 diluted serum
was precleared by incubation with protein A-Sepharose, urine was
collected and directly used for immunoprecipitation. Bile was col-
lected after opening the peritoneum, by aspiration directly from the
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main primary bile duct. Bile was diluted 1:3 with PBS prior to SDS-
PAGE or immunoprecipitation. Liver and MH 7777 membrane frac-
tions were prepared after homogenization by di¡erential centrifuga-
tion as described [1,29,32]. Membranes were resuspended in PBS/1%
Triton X-100 and completely solubilized for 2 h at 4‡C. The super-
natant after centrifugation at 100 000Ug contained the extracted
membrane preparation.
2.4. Induction of diseases
The main primary bile duct was ligated after opening the perito-
neum under anesthesia. The peritoneum was closed, and blood, liver
or urine were taken 2 days later. Hepatitis was induced by intraper-
itoneal injection of 2-amino-2-deoxy-D-galactose (0 h and 24 h,
400 mg/kg body weight) as described [27,33]. Injection of galactos-
amine (GalN) was repeated 24 h later. After 48 h blood, liver and
urine were taken. Normal healthy rats were used as a control for
GalN hepatitis- and MH 7777-bearing rats. As a control for rats
with bile duct ligation, the peritoneum of healthy rats was opened
and closed without further manipulation. MH 7777 cells were inocu-
lated into both hind legs of Bu¡alo rats as described previously [28].
3. Results
3.1. Characterization of C-CAM in serum, bile and urine
Western blot analysis did not detect C-CAM in the serum
of normal rats. In contrast, the anti-C-CAM antiserum pre-
cipitated a 100-kDa immunoreactive protein band. No speci¢c
immunoreactivity was found against IgG from preimmune
serum in the same Mr range, indicating that this 100-kDa
protein is identical with C-CAM (Fig. 1). All other detectable
proteins were found to bind unspeci¢cally to the protein A-
Sepharose complex, since they were not detected after pre-
treatment of the serum with protein A-Sepharose prior to
precipitation. Using the monoclonal antibody Be 9.2 for
Western blot detection C-CAM appeared as a distinct protein
band (Fig. 2a). Since unspeci¢cally binding proteins were not
accumulated, this strategy was also used for semi-quantitative
immunoprecipitation experiments. To check whether C-CAM
is shed by proteolytic attack, we compared the di¡erence in
Mr of liver and serum C-CAM (Fig. 2b). Serum C-CAM has
a slightly lower Mr than liver plasma membrane-bound
C-CAM. Antibodies speci¢c for the cytoplasmic tail of
C-CAM did not precipitate C-CAM from serum, indicating
shedding or limited proteolysis of C-CAM (Fig. 2c). We also
analyzed bile and urine for the presence of C-CAM. C-CAM
was detectable in the bile of normal rats by Western blotting.
Whereas transfected CHO cells express the long and the short
C-CAM isoforms, bile C-CAM shows several distinct protein
bands with slightly lower Mr ranging from 85 000 to 100 000.
Speci¢city was shown with the monoclonal antibodies 38.9
and Be 9.2 (Fig. 3a). In contrast, speci¢c antibodies did not
precipitate C-CAM from urine (Fig. 3b).
3.2. Serum level of C-CAM in rats su¡ering from liver diseases
C-CAM was then analyzed in serum from rats with bile
duct ligation, and in rats with induced hepatitis or hepatoma
(MH 7777). The bile duct was tied up and serum was taken
4 days later. Hepatitis was induced chemically by galactos-
amine injection. Immunoprecipitation of C-CAM (Fig. 4)
demonstrated that bile duct ligation caused a twofold increase
of C-CAM, but not of LI-cadherin, which was measured as a
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Fig. 1. Detection of C-CAM in rat serum. Immunoblot of liver
membrane protein fraction (Li) and serum proteins (Se) (50 Wg
each) with polyclonal anti-C-CAM antibodies without (a) or after
(b) C-CAM immunoprecipitation. 1: Pre-immune serum and 2:
anti-C-CAM serum were used for precipitation.
Fig. 2. Structural properties of serum-C-CAM. a: Immunoblot de-
tection of serum proteins (Se) with polyclonal anti-C-CAM antibod-
ies after precipitation. Precipitation was done before (3) and after
(+) preclearance with protein A-Sepharose. b: Comparison of the
Mr of liver C-CAM (Li) and serum C-CAM (Se) after precipitation
and Western blot detection with the mAb Be 9.2. c: Evidence for
loss of the cytoplasmic tail of serum C-CAM (Se) obtained by im-
munoprecipitation with an antiserum speci¢c for the cytoplasmic
tail of C-CAM followed by detection with the mAb Be 9.2; 1: Pre-
cipitation from serum, 2: precipitation from liver.
Fig. 3. C-CAM in bile liquid and urine. a, left: Western blot of
proteins from bile (B) and for comparison from transfected CHO
cells with a polyclonal antiserum (anti-C); (wt) wild type CHO cells,
(L) long and (S) short isoform expressing CHO transfectants. a,
right: C-CAM from bile (B) and for comparison from liver (Li) the
mAbs 38.9 and Be 9.2 were used after precipitation with the anti-C-
CAM antiserum. b: Western blot with a polyclonal antiserum (anti-
C) of proteins from urine (U) and for control from liver (Li) after
precipitation.
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control in the same sera. Tumor growth (MH 7777) also re-
sults in high concentrations of C-CAM in serum. GalN hep-
atitis leads to the highest increase of C-CAM (3^4-fold) with
no e¡ect on the serum level of LI-cadherin. To evaluate
whether the increased concentration of C-CAM is due to a
decrease in membrane-bound C-CAM, we prepared mem-
brane fractions of liver. Western blot analysis demonstrated
that in rats with bile duct ligation and GalN hepatitis part of
the C-CAM in serum results from shedding. The concentra-
tion of liver membrane-bound C-CAM is decreased to at least
a third of normal, while the concentration of LI-cadherin in
plasma membranes of damaged rat livers is unchanged. The
C-CAM concentration of liver plasma membrane fractions of
rats bearing MH 7777 was not a¡ected (Fig. 5).
3.3. C-CAM in urine of rats su¡ering from liver diseases
Urine of normal rats does not contain proteins v 68 kDa.
Surprisingly, the urine of diseased rats contains high concen-
trations of C-CAM (Fig. 6). The level of urine C-CAM is
similar in rats with bile duct ligation and in rats bearing
Morris hepatoma, and is highest in rats su¡ering from
GalN hepatitis. GalN hepatitis leads to a fourfold increase
in comparison with normal rats. In contrast, the albumin
concentration in urine was unchanged (data not shown) and
LI-cadherin was not detectable.
4. Discussion
Rat C-CAM is related to the CEA family (for review see
[34,35]) showing greatest similarity to mouse and human bili-
ary glycoproteins (bgp, BGP/human CD66a). The aim of this
study was to determine whether the serum C-CAM level de-
pends on in£ammation and whether C-CAM could be used as
a marker protein for these in£ammations. So far, there are no
data available for shedding of rat C-CAM. In view of the
functions of C-CAM, such as growth inhibition activity, its
loss would in£uence cell function in general.
We demonstrated by Western blotting that C-CAM is shed
into serum and bile. Since membrane domain localization may
be important for the degree of shedding by limited proteolysis,
we investigated for comparison another liver plasma mem-
brane-bound adhesion molecule, LI-cadherin [30], which is
known to be associated with the basolateral membrane do-
main of hepatocytes. It was shown that the serum concentra-
tion of C-CAM but not of LI-cadherin is increased during bile
duct ligation and GalN hepatitis. This is consistent with ex-
periments on human BGP [25,26,36]. In the rat model we
could show that large quantities of serum C-CAM arise
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Fig. 5. Detection of C-CAM and LI-cadherin in liver membrane
protein fractions of rats with induced liver diseases. (1) Healthy
rats, (2) rats with bile duct ligation, (3) rats with induced GalN hep-
atitis and (4) rats with a growing Morris hepatoma 7777. C-CAM
and LI-cadherin were precipitated with polyclonal antisera and de-
tected with mAb Be 9.2 and mAb 47.2, respectively.
Fig. 6. Detection of C-CAM and LI-cadherin in urine of rats with
induced liver diseases. (1) Healthy rats, (2) rats with bile duct liga-
tion, (3) rats with induced GalN hepatitis and (4) rats with a grow-
ing Morris hepatoma 7777. As a control C-CAM was precipitated
from liver (Li). Pre-immune serum was used for precipitation from
the urine of rats with GalN hepatitis as a second control (C).
C-CAM and LI-cadherin were precipitated with polyclonal antisera
and detected with mAb Be 9.2 and mAb 47.2, respectively.
Fig. 4. Detection of C-CAM and LI-cadherin in serum of rats with
induced liver diseases. (1) Healthy rats, (2) rats with bile duct liga-
tion, (3) rats with induced GalN hepatitis and (4) rats with a grow-
ing Morris hepatoma 7777. C-CAM and LI-cadherin were precipi-
tated with polyclonal antisera and detected with mAb Be 9.2 and
mAb 47.2, respectively.
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from the liver cell membrane itself. In contrast to LI-cadherin
the serum level of C-CAM is increased in cases of hepatoma.
This may re£ect the reduction of C-CAM expression in hep-
atoma plasma membrane, compared with liver plasma mem-
brane [1,37]. C-CAM expression in liver plasma membranes of
hepatoma-bearing rats is not reduced, indicating shedding
from hepatoma plasma membranes. The serum LI-cadherin
level is generally not in£uenced by the induced liver diseases.
The most surprising result of this study is that C-CAM is
detectable in urine of rats with liver diseases, especially in
rats su¡ering from hepatitis. This ¢nding is not a result of
disordered kidney function because neither LI-cadherin nor
albumin, the major protein component in serum, is detectable
in urine. The mechanism of C-CAM secretion into urine re-
mains to be clari¢ed.
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